Listen to high-grade lymphoma patient case studies, from UK haematologists.
The following case studies have been selected by the respective HCP to discuss their experience with Polivy®▼ (polatuzumab vedotin)+R-Benda in R/R DLBCL patients.
These case studies are not intended to be a full representation of Polivy in the R/R DLBCL patient population.
Polivy + R-Benda R/R DLBCL patient case studies
Listen to Dr David Tucker's presentation of a 72yr old triple-HIT R/R DLBCL patient treated with Polivy + R-Benda after 2 lines of prior therapy.
Duration 4 min 31 sec.
Listen to Dr Wendy Osborne discuss a second line R/R DLBCL patient treated with Polivy + R-Benda. Note: the patient presented here is not Wendy Osborne's patient and was originally presented as part of an EHA 2020 Symposium.
Duration 2 min 42 sec.
R-benda, rituximab and bendamustine; R/R, relapsed/refractory; DLBCL, diffuse large B-cell lymphoma; HCP, healthcare professional, EHA, European Haematology Association.
- Sehn LH et al. J Clin Oncol 2020;38(2):155–165.
Date of preparation: January 2021